Puma Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 185
- Market Cap
- $124.5M
- Introduction
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
- Conditions
- Advanced Malignant Solid Tumors
- Interventions
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01128842
- Locations
- 🇯🇵
Investigational Site, Tokyo, Japan
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT01111825
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸Western Regional Medical Center, Inc., Goodyear, Arizona, United States
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
- Conditions
- Advanced Malignant Solid Tumors
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00958724
- Locations
- 🇯🇵
Shizuoka Cancer Center, Shizuoka, Japan
🇯🇵The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Registration Number
- NCT00932464
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 479
- Registration Number
- NCT00915018
- Locations
- 🇫🇷
Service d'Oncologie et de Radiotherapie, Polyclinique Francheville, Perigueux, France
🇷🇴Institutul Oncologic Prof. Dr. Ion Chiricuţă, Cluj-Napoca, Cluj, Romania
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 2840
- Registration Number
- NCT00878709
- Locations
- 🇺🇸
Mercy Hospital Oncology/Hematology Center, Portland, Maine, United States
🇺🇸Cancer Specialists of South Texas, P.A., Corpus Christi, Texas, United States
🇺🇸University Hospitals, Cleveland Medical Center, Cleveland, Ohio, United States
Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00864487
Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00860223
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
- Conditions
- NeoplasmsMalignant Carcinoma
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00838539
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇫🇷Institut Gustave Roussy, Villejuif, France
Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00814060